Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Miltenyi Biotec


Contact Details:
1130 Woodlake Dr
Cardiff
CA
92007
United States of America
Tel:760 942 7414
Fax:760 942 9521
Email:

Loading...

Recent Publications by Miltenyi Biotec:

Enhanced dendritic cell-induced immune responses mediated by the novel C-type lectin receptor mDCAR1.
The dendritic cell (DC) immunoreceptors (DCIR) and DC-immunoactivating...
11th November, 2009
Miltenyi Biotec, J Immunol. 2009 Oct 15;183(8):5069-78. Epub 2009 Sep 28.
DOI Direct Link
Absolute quantification of microRNAs by using a universal reference.
MicroRNAs (miRNAs) are a species of small RNAs approximately...
29th October, 2009
Miltenyi Biotec GmbH, 51429 Bergisch Gladbach, Germany. RNA. 2009 Oct 27.
DOI Direct Link
Generation of single-cell suspensions from mouse neural tissue.
Within the nervous system, hundreds of neuronal and glial cell types have...
26th August, 2009
Miltenyi Biotec GmbH, Germany. J Vis Exp. 2009 Jul 7;(29). pii: 1267. doi: 10.3791/1267.
DOI Direct Link
Standardized preparation of single-cell suspensions from mouse lung tissue using the gentleMACS Dissociator.
The preparation of single-cell suspensions from tissues is an important...
11th August, 2009
Miltenyi Biotec,GmbH. J Vis Exp. 2009 Jul 2;(29). pii: 1266. doi: 10.3791/1266.
DOI Direct Link
Ubiquitin-binding domains and their role in the DNA damage response.
The modification of eukaryotic proteins by covalent attachment of...
25th June, 2009
Bioinformatics Group, Miltenyi Biotec GmbH, Friedrich-Ebert-Strasse 68, DNA Repair (Amst). 2009 Apr 5;8(4):544-56. Epub 2009 Feb 12.
DOI Direct Link

View more Miltenyi Biotec research publications.

Press Releases on Miltenyi Biotec:

BioPortfolio Logo
Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells 29th October, 2009 Miltenyi Biotec GmbH
BERGISCH GLADBACH, Germany, October 29 /PRNewswire/ -- Miltenyi Biotec announces the treatment of the first patient in a phase III clinical trial termed PERFECT. The trial aims at determining
Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings 20th May, 2009 Miltenyi Biotec GmbH
BERGISCH GLADBACH, Germany, May 20 /PRNewswire/ -- Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and
BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 5th May, 2009 BioInformatics, LLC
ARLINGTON, Va., May 5 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts
BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 7th April, 2009 BioInformatics, LLC
ARLINGTON, Va., April 7 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. As a result of the March 9,
The New MACSQuant(TM) Analyzer Combines Cell Enrichment and Flow Cytometry 16th January, 2009
BERGISCH GLADBACH, Germany, January 16 /PRNewswire/ -- Miltenyi Biotec announces the worldwide release of the MACSQuant(TM) Analyzer, a novel and compact flow cytometer for multiparameter cell

BioNews Results for Miltenyi Biotec:

Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial ...
PipelineReview:  Oct 29 2009 11:50PM Matching: miltenyi biotec
Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial 'PERFECT' Using Autologous CD133+ Bone M
Pharmacy Choice:  Oct 30 2009 1:44AM Matching: miltenyi biotec
Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial 'PERFECT' Using Autologous CD133+ Bone M
Montana's News Station:  Oct 29 2009 5:55PM Matching: miltenyi biotec
Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells
Individual.com:  Oct 29 2009 3:54PM Matching: miltenyi biotec

Miltenyi Biotec Clinical Trials:

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Miltenyi Biotec Patents:

US Patent No.Title
7554657 Accomodating device for specimen slides
5779892 Magnetic separator with magnetic compensated release mechanism for separating biological material
5786161 Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
5916818 Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
6190870 Efficient enrichment and detection of disseminated tumor cells

View more Miltenyi Biotec patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 447 times since April 2007, the link to the organisation's website has been followed 0 times

Recent Search Terms used to find this page: miltenyi market | mitenyi | miltenyi biotec | miltenyi biotec | gentleMACS Dissociator pricing | miltenyi quote | miltenyi biotec | flow cytometer miltenyi | MACSQuant | .

Search for more companies in Cardiff

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Miltenyi Biotec

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.